New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
12:25 EDTBLUE, BLUE, BMRN, BMRN, CELG, CELG, CLDN, CLDN, MDGN, MDGN, QURE, QURE, SGMO, SGMO, AGTC, AGTC, ALGN, ALGNPiper Jaffray biopharm analyst holds an analyst/industry conference call
Biopharmaceuticals Analyst Schimmer discusses gene therapy and highlights public and private companies involved in the field, as well as the large-cap pharma partnerships on an Analyst/Industry conference call. Relevant companies AGTC, ALGN, BLUE, BMRN, CELG, CLDN, MDGN, QURE and SGMO may be included on the Analyst/Industry conference call to be held on June 18 at 2 pm.
News For AGTC;ALGN;BLUE;BMRN;CELG;CLDN;MDGN;QURE;SGMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
June 29, 2015
19:01 EDTCELGOn The Fly: After Hours Movers
HIGHER: Juno Therapeutics (JUNO), up 38.4% after announcing immunotherapy collaboration with Celgene (CELG)... Kite Pharma (KITE) and Lion Biotechnologies (LBIO) are up 8.7% and 5.7% respectively, following Juno's collaboration with Celgene. DOWN AFTER EARNINGS: CHC Group (HELI), down 8%... Apollo Education (APOL), down 6.2%. ALSO LOWER: EnteroMedics (ETRM), down 12.4% after filing to sell common stock and warrants... Celgene (CELG), down 1% after Juno announces immunotherapy collaboration.
18:09 EDTCELG, BLUEJuno surges after Celgene collaboration, CAR-T peers follow
Subscribe for More Information
16:09 EDTCELGCelgene, Juno Therapeutics announce ten year collaboration
Celgene (CELG) and Juno Therapeutics (JUNO) announced a global collaboration for the development and commercialization of immunotherapies. The two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on Chimeric Antigen Receptor Technology and T Cell Receptor technologies. Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno’s oncology and cell therapy auto-immune product candidates, including Juno’s CD19 and CD22 directed CAR-T product candidates. B-Cell Maturation Antigen is excluded as a target in this collaboration. Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno’s oncology and cell therapy auto-immune product candidates, including Juno’s CD19 and CD22 directed CAR-T product candidates. B-Cell Maturation Antigen is excluded as a target in this collaboration. For Juno-originated programs co-developed under the collaboration: Juno will be responsible for research and development in North America and will retain commercialization rights in those territories; Celgene will be responsible for development and commercialization in the rest of the world, and will pay Juno a royalty on sales in those territories; and Celgene has certain co-promotion options: Celgene will initially be eligible to select two programs, excluding CD19 and CD22, to be subject to a global profit sharing agreement under which the companies will share worldwide expenses and profits equally, except in China; and Additionally, subject to additional obligations, Celgene may select a third program. Juno will have the option to enter into a co-development and co-commercialization agreement on certain Celgene-originated development candidates that target T Cells. For any such Celgene-originated programs co-developed under the collaboration: The parties will share global costs and profits with 70% allocated to Celgene and 30% allocated to Juno; and Celgene will lead global development and commercialization, subject to a Juno co-promote option in the US and certain EU territories. Upon closing, Juno will receive an upfront payment of approximately $150M, and in addition Celgene will purchase 9,137,672 shares of Juno’s common stock at $93.00 per share. In conjunction with this stock purchase: Celgene will receive the right to nominate a member to Juno’s board of directors; During the 10-year term of the collaboration, Celgene will have the right to purchase additional equity in Juno during specified windows and at specified market premiums subject to satisfaction of certain conditions by each party including Juno opting in on select Celgene programs, such that, at a maximum, Celgene could own up to 30% of Juno’s common stock then outstanding; and Celgene has entered into a standstill agreement and agreed to certain lock-up provisions on its share ownership. This transaction has been approved by the boards of directors of both companies. Celgene and Juno currently expect to complete the transaction during the third quarter of 2015, subject to the expiration or termination of applicable waiting periods under all applicable antitrust laws and satisfaction of other usual and customary closing conditions.
16:08 EDTCELGJuno jumps 45% after announcing immunotherapy collaboration with Celgene
Subscribe for More Information
16:07 EDTCELGCelgene, Juno Therapeutics announce ten year collaboration
Subscribe for More Information
12:53 EDTBMRNSarepta NDA submission for eteplirsen done ahead of schedule, says Piper Jaffray
Piper Jaffray noted that Sarepta (SRPT) completed its rolling NDA submission for eteplirsen ahead of schedule and the firm believes that concurrent advisory committee meetings for its DMD drug and BioMarin's (BMRN) drisapersen could take place this fall. The firm has a Neutral rating and $20 price target on Sarepta and Overweight rating and $147 target on BioMarin.
08:36 EDTBMRNBioMarin announces FDA acceptance of drisapersen NDA
Subscribe for More Information
June 26, 2015
11:32 EDTCELGCelgene looks to protect itself from Kyle Bass patent challenges, WSJ says
Subscribe for More Information
10:02 EDTCLDNCelladon discloses further 50% workforce reduction
In a regulatory filing, Celladon disclosed that its board approved an additional 50% reduction of the company's 17 current remaining full-time employees who were not included in the workforce reduction announced on April 30, 2015. The company expects that this group of employees, which constitutes the remainder of the company’s research and development staff, will be separated from the company during the third quarter of 2015. The company estimates that it will incur incremental aggregate cash charges of approximately $1.33M associated with this workforce reduction. This reduction is in addition to the previously announced 50% workforce reduction announced on April 30, 2015.
09:10 EDTCLDNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Finish Line (FINL), up 6.5%... Nike (NKE), up 3.2%. ALSO HIGHER: GigaMedia (GIGM), up 14.6% after agreeing to acquire 70% equity interest in Strawberry Cosmetics. DOWN AFTER EARNINGS: Micron Technology (MU), down 14.8%. ALSO LOWER: Celladon (CLDN), down 42.7% after planning to suspend further R&D of MYDICAR program... Real Goods Solar (RGSE), down 18.4% after raising $5M in a common stock and warrant offering... SanDisk (SNDK), down 3.3% after Micron Technology reports quarterly results... Alder Biopharmaceuticals (ALDR), down 2.6% after 4.49M share Secondary priced at $44.50... Sotherly Hotels (SOHO), down 2% after 3M share Secondary priced at $7.11.
08:57 EDTALGNClearCorrect says granted request for fourth Align patent reexam, Bloomberg says
A ClearCorrect spokeswoman stated to Bloomberg via e-mail that the company was granted a fourth request for reexamination of an Align Technology patent yesterday by the USPTO, the news service reported. An Align Technology spokeswoman remarked that the grant for fourth reexamination was “not unexpected” and said the patent was previously found to be valid during an ITC investigation, the report added.
06:02 EDTCLDNCelladon plans to suspend further R&D of MYDICAR program
Subscribe for More Information
June 25, 2015
16:03 EDTBMRNBioMarin announces EMA validates MAA for drisapersen for treatment of DMD
Subscribe for More Information
June 24, 2015
09:07 EDTBLUECAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
06:06 EDTBLUEbluebird bio 2.94M share Spot Secondary priced at $170.00
Subscribe for More Information
June 23, 2015
16:01 EDTBLUEbluebird bio files to sell $400M in common stock
Subscribe for More Information
11:25 EDTMDGNMedgenics management to meet with Piper Jaffray
Subscribe for More Information
07:49 EDTBMRNPTC Therapeutics risk lowered by symposium, says Oppenheimer
Subscribe for More Information
07:25 EDTBMRNPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
08:03 EDTBLUEKite Pharma, bluebird bio announce strategic collaboration
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use